Sophisticated computational tools have guided Relay Therapeutics in its efforts to develop new drugs based on analysis of the movement and shape of disease-causing proteins.
Now the Cambridge, MA, biotech is looking to tap the public markets to bulk up company coffers and get its two lead drug candidates into mid-stage clinical trials as potential treatment for cancers.
In documents filed Wednesday with regulators, Relay set a preliminary target of $200 million for its IPO. The company is looking to list on the Nasdaq exchange under the ticker symbol “RLAY.”
Founded in 2016, Relay has raised $520 million across three rounds… Read more »
UNDERWRITERS AND PARTNERS
